GTBIF · Green Thumb Industries Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Green Thumb posted 5% revenue growth to $307M and $84M normalized EBITDA in Q2 2026, but margin pressure from brand licensing fees and team investments weighed on profitability. The company is preparing for an uplisting and federal rescheduling progress, with Virginia adult-use set for July 1, 2027 and a new Texas conditional license secured.
- + Q2 revenue rose 5% YoY to $307M, driven by Minnesota adult-use launch and CPG growth.
- + Virginia adult-use authorized for July 1, 2027 and Texas conditional license secured, opening growth catalysts in markets covering ~12% of U.S. population.
- + DEA Schedule III reclassification of medical cannabis provides 280E tax relief and enables uplisting preparations.
- + Repurchased ~7.9M shares for $48.3M at average $6.11 in Q2, with $62.3M remaining authority.
- + Strong balance sheet with $283.6M cash and $29M operating cash flow provides flexibility for growth investment.
- − Gross margin compressed to 45% from 50% YoY due to $17.5M RYTHM brand licensing fees and price compression.
- − SG&A rose to 38% of revenue from 36% YoY due to compensation changes and retail expansion costs.
- − Normalized EBITDA margin declined to 27.5% from 28.2% YoY as deliberate team investments pressured margins.
- − Pricing compression remains a headwind; same-store sales declined 1.1% on a 103-store base.
- − Q3 revenue expected sequentially flat due to ongoing pricing pressure; potential RYTHM consolidation will change reported results.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GTBIF
this stock
Green Thumb Industries Inc.
|
$1.53B | -17.7% | +3.4% | — | 2.4% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GTBIF | -14.7% | -11.6% | -1.9% | -0.6% | -17.8% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -14.5% | -11.2% | -14.1% | -1.5% | -30.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.